TY - JOUR T1 - Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study JF - medRxiv DO - 10.1101/2020.04.25.20079079 SP - 2020.04.25.20079079 AU - Xiu Lan AU - Chuxiao Shao AU - Xu Zeng AU - Zhenbo Wu AU - Yanyan Xu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/29/2020.04.25.20079079.abstract N2 - Objectives This study aimed to evaluate the antiviral efficacy of lopinavir/ritonavir alone or combined with arbidol in the treatment of hospitalized patients with common coronavirus disease-19 (COVID-19).Methods In this retrospective observational study, COVID-19 hospitalized patients were identified and divided into two groups based on the antiviral agents used during their hospitalization. Group-LR patients were treated with single antiviral drug of lopinavir-ritonavir. Group-LR+Ar patients were treated with lopinavir-ritonavir combined with arbidol for antiviral therapy at least 3 days. Patients were assessed for different clinical outcomes.Results A total of 34 and 39 patients were identified for Group-LR and Group-LR+Ar, respectively. Treatment with lopinavir–ritonavir alone was not difference from lopinavir-ritonavir combined with arbidol in overall cure rate of COVID-19 hospitalized patients (92.3% and 97.1%, respectively). In a modified intention-to-treat analysis, lopinavir–ritonavir combined with abidol led to a median time of hospital stay that was shorter by 1.5 days than group-LR (12.5 days vs. 14 days). The percentages of COVID-19 RNA clearance was 92.3 in group-LR and 97.1 in group-LR+Ar. The mean time of virus turning negative was 11.5±9.0 days in group-LR+Ar that were longer than group-LR. Treatment of lopinavir-ritonavir combined with arbidol did not significantly accelerate main symptoms improvement and promote the image absorption of pulmonary inflammation.Conclusion No benefit was observed in the anti-virus effect of lopinavir–ritonavir combined with arbidol compared with lopinavir-ritonavir alone in the hospitalized patients with COVID-19. More clinical observations in COVID-19 patients may help to confirm or exclude the effect of antiviral agents.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000030391Funding StatementThis work was supported by the High Level Talented Person Cultivating Program of Lishui Science and Technology Bureau under Grant No.2018RC06, Zhejiang Provincial Natural Science Foundation of China under Grant no. LY18H300007, and Zhejiang TCM science and technology program under Grant No.2013ZB148.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study have been deposited in the figshare repository (DOI:10.6084/m9.figshare.12195735). https://figshare.com/articles/COVID19_inpatient_cases_data_xls/12195735 ER -